General Principles
Modern management of rheumatic disease in pregnancy starts with disease control before conception, careful medication review, and multidisciplinary care involving rheumatology and maternal-fetal medicine.
Clinical points
- Pregnancy outcomes are usually best when disease is quiescent or low activity before conception.
- Medication changes should ideally occur before pregnancy rather than after a positive test.
- Autoantibody profile matters: antiphospholipid antibodies and anti-SSA/SSB antibodies can substantially change management.
- Active renal, cardiopulmonary, neurologic, or severe systemic disease may make pregnancy substantially higher risk.
Systemic Lupus Erythematosus (Lupus)
Lupus remains the connective tissue disease most often discussed in high-risk obstetrics because pregnancy complications depend strongly on disease activity, nephritis history, antibody status, hypertension, and medication continuity.
Clinical points
- Pregnancy is generally safest when lupus is clinically quiescent before conception.
- Hydroxychloroquine is commonly continued and is an important component of modern lupus pregnancy care.
- Assess for lupus nephritis, antiphospholipid antibodies, anti-SSA/SSB antibodies, hypertension, and prior thrombosis.
- Lupus pregnancies often merit aspirin prophylaxis, serial growth assessment, and antenatal surveillance depending on risk profile.
Lupus-specific counseling emphasis
Important recurring topics include prepregnancy counseling, hydroxychloroquine use, lupus nephritis history, APS risk, anti-SSA/SSB status, fetal growth surveillance, and differentiating lupus flare from preeclampsia later in pregnancy.
Anti-Ro/SSA and Anti-La/SSB Antibodies
Anti-SSA/SSB antibodies are especially important because of their association with neonatal lupus and congenital heart block, even outside classic lupus.
Clinical points
- These antibodies matter in lupus, Sjögren syndrome, mixed connective tissue disease, and sometimes undifferentiated autoimmune disease.
- Counsel patients about the risk of neonatal lupus and immune-mediated fetal conduction disease.
- Management varies by antibody status, prior affected child, and local fetal cardiology practice.
- Modern recommendations are more selective than older practice regarding routine serial PR-interval surveillance.
Behçet Disease
Behçet disease is less common in obstetric practice but may still require individualized planning for disease activity, thrombosis risk, and medication compatibility.
Clinical points
- Pregnancy course is variable, and symptom behavior may differ among mucocutaneous, ocular, and systemic disease phenotypes.
- Review thrombosis history, vascular disease, neurologic involvement, and treatment needs before or early in pregnancy.
- Care is best individualized with rheumatology input because high-quality pregnancy-specific data remain limited.
Reference links
The older 1997 Behçet article on the legacy page has largely been superseded by broader modern reproductive rheumatology guidance.
Rheumatoid Arthritis
Rheumatoid arthritis often improves during pregnancy for some patients, but flares can still occur, and postpartum disease activity is a frequent issue.
Clinical points
- Pregnancy planning should focus on disease control and transition to pregnancy-compatible therapy before conception.
- Some patients improve during pregnancy, but postpartum flare risk remains clinically important.
- Medication compatibility, breastfeeding plans, and postpartum treatment access should be discussed early.
Scleroderma / Systemic Sclerosis
Scleroderma in pregnancy ranges from manageable limited disease to very high-risk disease with renal crisis, interstitial lung disease, or pulmonary hypertension.
Clinical points
- Assess renal disease, pulmonary hypertension, interstitial lung disease, cardiac involvement, and gastrointestinal nutritional issues before pregnancy.
- Pregnancy may be very high risk in severe cardiopulmonary or renal disease.
- Medication review is critical because some standard rheumatology treatments are contraindicated in pregnancy.
Giant Cell Arteritis / Vasculitis
Giant cell arteritis itself is uncommon in pregnancy, but vasculitis more broadly can present major maternal risk depending on organ involvement and treatment needs.
Clinical points
- Pregnancy risk depends less on disease label alone and more on current activity, organ threat, vascular complications, and medication exposure.
- Severe vasculitis with renal, pulmonary, neurologic, or vascular involvement requires tertiary multidisciplinary care.
- Legacy isolated articles are less useful today than broad reproductive rheumatology guidelines.
Medication & Reproductive Guidance
Medication compatibility has changed substantially since the original page was written. Modern guidance is more explicit about which antirheumatic drugs may be continued and which should be stopped before conception.
General medication themes
- Pregnancy-compatible drugs commonly include hydroxychloroquine and selected other immunomodulatory therapies depending on diagnosis and dose.
- Some biologics are increasingly considered acceptable in pregnancy, especially when disease control would otherwise be poor.
- Methotrexate and mycophenolate remain classic examples of medications requiring discontinuation before conception.
- Medication decisions should balance maternal disease control and fetal safety rather than reflexively stopping effective therapy.